USS Investment Management Ltd lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 5.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 412,085 shares of the biopharmaceutical company’s stock after acquiring an additional 19,800 shares during the period. USS Investment Management Ltd’s holdings in Bristol Myers Squibb were worth $25,733,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Berger Financial Group Inc increased its stake in shares of Bristol Myers Squibb by 10.0% during the 3rd quarter. Berger Financial Group Inc now owns 4,164 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 380 shares during the last quarter. Tyche Wealth Partners LLC purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter worth about $530,000. Focus Advisor Solutions LLC lifted its holdings in shares of Bristol Myers Squibb by 82.2% during the 3rd quarter. Focus Advisor Solutions LLC now owns 175,777 shares of the biopharmaceutical company’s stock worth $10,969,000 after acquiring an additional 79,299 shares during the period. Checchi Capital Advisers LLC boosted its position in shares of Bristol Myers Squibb by 13.6% in the third quarter. Checchi Capital Advisers LLC now owns 9,936 shares of the biopharmaceutical company’s stock worth $620,000 after acquiring an additional 1,187 shares during the last quarter. Finally, Bluebird Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the third quarter worth approximately $200,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Insider Buying and Selling
In other news, Director Julia A. Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the stock. Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research note on Wednesday, August 5th. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. JPMorgan Chase & Co. lifted their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Cantor Fitzgerald lowered their price objective on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $65.46.
Check Out Our Latest Analysis on BMY
Bristol Myers Squibb Stock Performance
Bristol Myers Squibb stock opened at $58.33 on Friday. The company has a market cap of $119.23 billion, a price-to-earnings ratio of 12.93, a price-to-earnings-growth ratio of 0.31 and a beta of 0.20. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The stock’s 50-day moving average is $61.55 and its 200-day moving average is $60.42.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. The business had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.63 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.
Bristol Myers Squibb Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is 55.88%.
Latest Bristol Myers Squibb News
These are some of the BMY news items that stood out recently:
- Positive Sentiment: A second investigational drug candidate from BMS’s protein-degradation partnership with Evotec received FDA IND acceptance, advancing another potential medicine toward clinical testing. The partnership’s first candidate entered Phase 1 in March 2026. Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance
- Neutral Sentiment: BMS highlighted clinical programs in blood cancers and rare blood disorders at ASH 2026. The announcement points to broad pipeline activity, but the available report does not specify results likely to change near-term expectations. Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
- Negative Sentiment: Dividend-focused coverage underscores concern about BMS’s looming Eliquis patent cliff and the implications for future earnings and dividend coverage. 3 Big Pharma Dividend Stocks Built for Retirement Income
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Recommended Stories
- Five stocks we like better than Bristol Myers Squibb
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
